Mcquade Phd News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Mcquade Phd. Real-time updates on events, politics, business and more.

Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe

July 22, 2022

Press release content from Business Wire. The AP news staff was not involved in its creation.

United States United Kingdom Peter Greenleaf Sue Evans Dana Lynch European Union

Source: apnews.com

Aurinia Pharmaceuticals Inc.: Aurinia Announces Positive CHMP Opinion for LUPKYNIS (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe

July 22, 2022

Positive CHMP opinion is based on a comprehensive submission including data from the pivotal AURORA 1 efficacy study and the AURORA 2 continuation study, demonstrating voclosporin to be safe and well

United States United Kingdom Peter Greenleaf Sue Evans Dana Lynch Aurinia Pharmaceuticals Inc

Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Mcquade Phd News Today

Aurinia Announces Positive CHMP Opinion for LUPKYNIS&#xAE; (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe

Aurinia Pharmaceuticals Inc.: Aurinia Announces Positive CHMP Opinion for LUPKYNIS (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe

Explore More Categories

Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe